{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:04:24Z","timestamp":1784221464085,"version":"3.55.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,4,28]]},"DOI":"10.2967\/jnumed.125.271137","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:15:18Z","timestamp":1784218518000},"page":"jnumed.125.271137","source":"Crossref","is-referenced-by-count":0,"title":["Combining an \u03b1\n                    <sub>v<\/sub>\n                    \u03b2\n                    <sub>6<\/sub>\n                    -Targeted\n                    <sup>177<\/sup>\n                    Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer"],"prefix":"10.2967","author":[{"given":"Tanushree","family":"Ganguly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2026071609150881000_jnumed.125.271137v1.1","unstructured":"Cancer facts and figures 2025. American Cancer Society website. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf. Accessed May 7, 2026."},{"key":"2026071609150881000_jnumed.125.271137v1.2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/cancers14040985","article-title":"Current limitations and novel perspectives in pancreatic cancer treatment","volume":"14","author":"Robatel","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026071609150881000_jnumed.125.271137v1.3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4251\/wjgo.v12.i2.182","article-title":"FOLFIRINOX vs gemcitabine\/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study","volume":"12","author":"Cho","year":"2020","journal-title":"World J Gastrointest Oncol."},{"key":"2026071609150881000_jnumed.125.271137v1.4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/path.5320","article-title":"The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy","volume":"249","author":"Reader","year":"2019","journal-title":"J Pathol."},{"key":"2026071609150881000_jnumed.125.271137v1.5","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2014.1741"},{"key":"2026071609150881000_jnumed.125.271137v1.6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clon.2020.10.020","article-title":"Peptide receptor radionuclide therapy\u2014prospects for personalised treatment","volume":"33","author":"Sundl\u00f6v","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2026071609150881000_jnumed.125.271137v1.7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol."},{"key":"2026071609150881000_jnumed.125.271137v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y"},{"key":"2026071609150881000_jnumed.125.271137v1.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264749"},{"key":"2026071609150881000_jnumed.125.271137v1.10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3390\/pharmaceutics15122761","article-title":"DNA damage by radiopharmaceuticals and mechanisms of cellular repair","volume":"15","author":"Khazaei Monfared","year":"2023","journal-title":"Pharmaceutics."},{"key":"2026071609150881000_jnumed.125.271137v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.09.019"},{"key":"2026071609150881000_jnumed.125.271137v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"2026071609150881000_jnumed.125.271137v1.13","doi-asserted-by":"publisher","DOI":"10.2174\/1574892813666180305165256"},{"key":"2026071609150881000_jnumed.125.271137v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3577"},{"key":"2026071609150881000_jnumed.125.271137v1.15","first-page":"89","article-title":"The role of olaparib in metastatic pancreatic cancer","volume":"4","author":"Chi","year":"2021","journal-title":"Cancer Med J."},{"key":"2026071609150881000_jnumed.125.271137v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"2026071609150881000_jnumed.125.271137v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"2026071609150881000_jnumed.125.271137v1.18","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep."},{"key":"2026071609150881000_jnumed.125.271137v1.19","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","article-title":"Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer","volume":"51","author":"Rauch","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026071609150881000_jnumed.125.271137v1.20","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15311"},{"key":"2026071609150881000_jnumed.125.271137v1.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268902"},{"key":"2026071609150881000_jnumed.125.271137v1.22","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41(suppl)","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026071609150881000_jnumed.125.271137v1.23","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers15112975","article-title":"Peptide receptor radionuclide therapy (PRRT): innovations and improvements","volume":"15","author":"Merola","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026071609150881000_jnumed.125.271137v1.24","first-page":"P1297","article-title":"The ratio of total uptake volume on DOTATATE vs FDG PET is a predictive marker of treatment efficacy of Lu-177-DOTATATE in metastatic pheochromocytoma [abstract]","volume":"64","author":"Lin","year":"2023","journal-title":"J Nucl Med."},{"key":"2026071609150881000_jnumed.125.271137v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"2026071609150881000_jnumed.125.271137v1.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"2026071609150881000_jnumed.125.271137v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01469-9"},{"key":"2026071609150881000_jnumed.125.271137v1.28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.13.978"},{"key":"2026071609150881000_jnumed.125.271137v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjy072"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:15:21Z","timestamp":1784218521000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":29,"alternative-id":["10.2967\/jnumed.125.271137"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271137","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}